MiNK Therapeutics, Inc.
General ticker "INKT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $43.4M (TTM average)
MiNK Therapeutics, Inc. follows the US Stock Market performance with the rate: 13.1%.
Estimated limits based on current volatility of 6.1%: low 12.63$, high 14.27$
Factors to consider:
- Total employees count: 23 (-25.8%) as of 2024
- Top business risk factors: Operational and conduct risks, Product candidate success, Clinical trial delays, Labor/talent shortage/retention, Third-party risks
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [5.88$, 17.89$]
- 2026-12-31 to 2027-12-31 estimated range: [4.09$, 13.03$]
Financial Metrics affecting the INKT estimates:
- Negative: with PPE of -4.0 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -11863.09 <= 0.07
- Negative: Shareholder equity ratio, % of -99.92 <= 19.49
- Positive: Investing cash flow per share per price, % of 0 > -0.65
- Negative: negative Net income
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term INKT quotes
Long-term INKT plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $22.92MM | $11.29MM | $12.49MM |
| Operating Income | $-22.92MM | $-11.29MM | $-12.49MM |
| Non-Operating Income | $0.46MM | $0.50MM | $-0.01MM |
| R&D Expense | $15.49MM | $6.34MM | $5,757.49MM |
| Income(Loss) | $-22.46MM | $-10.78MM | $-12.49MM |
| Profit(Loss)* | $-22.46MM | $-10.78MM | $12,469.27MM |
| Stockholders Equity | $-18.06MM | $-19.59MM | $-14.23MM |
| Assets | $4.55MM | $5.72MM | $14.24MM |
| Operating Cash Flow | $-15.76MM | $-9.56MM | $-5,925.17MM |
| Capital expenditure | $0.07MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $-0.07MM | $0.00MM | $0.00MM |
| Financing Cash Flow | $-0.41MM | $10.82MM | $14,721.90MM |
| Earnings Per Share** | $-6.54 | $-2.88 | $2,920.20 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.